FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1620-1622 October 12, 2006 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial recently demonstrated that raloxifene, a selective estrogen-receptor modulator, was as effective as tamoxifen in reducing the risk of invasive breast cancer in postmenopausal women.¹ However, fewer noninvasive breast cancers were detected in women who received tamoxifen than in women who received raloxifene (1.51 cases per 1000 women vs. 2.11 cases per 1000 women),¹ suggesting that raloxifene may not prevent noninvasive breast cancer. Here, we present evidence that mammary atypia developed during raloxifene therapy in a woman at high risk for breast . . . [Full Text of this Article]

This article has been cited by other articles:

• Baker, J. C. Jr., Ostrander, J. H., Lem, S., Broadwater, G., Bean, G. R., D'Amato, N. C., Goldenberg, V. K., Rowell, C., Ibarra-Drendall, C., Grant, T., Pilie, P. G., Vasilatos, S. N., Troch, M. M., Scott, V., Wilke, L. G., Paisie, C., Rabiner, S. M., Torres-Hernandez, A., Zalles, C. M., Seewaldt, V. L. (2008). ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention. Cancer Epidemiol. Biomarkers Prev. 17: 1884-1890 [Abstract] [Full Text]  
• Bean, G. R., Bryson, A. D., Pilie, P. G., Goldenberg, V., Baker, J. C. Jr., Ibarra, C., Brander, D. M.U., Paisie, C., Case, N. R., Gauthier, M., Reynolds, P. A., Dietze, E., Ostrander, J., Scott, V., Wilke, L. G., Yee, L., Kimler, B. F., Fabian, C. J., Zalles, C. M., Broadwater, G., Tlsty, T. D., Seewaldt, V. L. (2007). Morphologically Normal-Appearing Mammary Epithelial Cells Obtained from High-Risk Women Exhibit Methylation Silencing of INK4a/ARF. Clin. Cancer Res. 13: 6834-6841 [Abstract] [Full Text]